Although metformin monotherapy had little therapeutic benefit in highly aggressive tumors, the combination of metformin and anti-PD-1/PD-L1 blockade resulted in improved intratumoral T-cell function and tumor clearance in vivo (10). This evidence concerns the gene PDCD1 and neoplasm.